Breast Cancer
January 2015
This bulletin covers aspects of breast cancer, and should be of interest to multidisciplinary teams
working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
GENERAL
Gultekin M, Yazici O, Eren G, et al. (2014). Impact of locoregional treatment on survival in
patients presented with metastatic breast carcinoma. Breast 23,6:775-783.
Zurrida S and Veronesi U. (2015). Milestones in breast cancer treatment. Breast Journal
21,1:3-12.
COMBINED MODALITY THERAPIES
Agarwal S and Agarwal J. (2015). Radiation delivery in patients undergoing therapeutic
nipple-sparing mastectomy. Annals of Surgical Oncology 22,1:46-51.
Bekelman JE, Sylwestrzak G, Barron J, et al. (2014). Uptake and costs of hypofractionated
vs conventional whole breast irradiation after breast conserving surgery in the United
States, 2008-2013. JAMA 312,23:2542-2550.
Boileau JF, Poirier B, Basik M, et al. (2015). Sentinel Node Biopsy After Neoadjuvant
Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study.
Journal of Clinical Oncology 33,3:258-264.
Donker M, van Tienhoven G, Straver ME, et al. (2014). Radiotherapy or surgery of the axilla
after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a
randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncology
15,12:1303-1310.
Kaidar-Person O, Kuten A, Belkacemi Y, et al. (2014). Primary systemic therapy and whole
breast irradiation for locally advanced breast cancer: a systematic review. Critical Reviews
in Oncology-Hematology 92,2:143-152.
Pernin V, Belin L, Cottu P, et al. (2014). Radiotherapy associated with concurrent
bevacizumab in patients with non-metastatic breast cancer. Breast 23,6:816-820.
Walsh SM, Lowery AJ, Prichard RS, et al. (2014). Postmastectomy radiotherapy: indications
and implications. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland
12,6:310-315.
DRUG & TARGETED THERAPY
Budd GT, Barlow WE, Moore HC, et al. (2015). SWOG S0221: A Phase III Trial Comparing
Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. Journal of Clinical
Oncology 33,1:58-64.
Clemens MR, Gladkov OA, Gartner E, et al. (2015). Phase II, multicenter, open-label,
randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2negative metastatic breast cancer. Breast Cancer Research & Treatment 149,1:171-179.
Gligorov J, Doval D, Bines J, et al. (2014). Maintenance capecitabine and bevacizumab
versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients
with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase
3 trial. Lancet Oncology 15,12:1351-1360.
Goldstein LJ, Gurtler J, Del Prete SA, et al. (2014). Trabectedin as a single-agent treatment
of advanced breast cancer after anthracycline and taxane treatment: a multicenter,
randomized, phase II study comparing 2 administration regimens. Clinical Breast Cancer
2
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
14,6:396-404.
Hudis C and Dang C. (2015). The development of dose-dense adjuvant chemotherapy.
Breast Journal 21,1:42-51.
Lam SW, de Groot SM, Honkoop AH, et al. (2014). Paclitaxel and bevacizumab with or
without capecitabine as first-line treatment for HER2-negative locally recurrent or
metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. European
journal of cancer 50,18:3077-3088.
Lee J, Kim J, Chang E, et al. (2014). A Phase II Trial of Neoadjuvant Chemotherapy with
Genexol (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer. Journal of Breast
Cancer 17,4:344-349.
Luck HJ, Lubbe K, Reinisch M, et al. (2015). Phase III study on efficacy of taxanes plus
bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast
cancer. Breast Cancer Research & Treatment 149,1:141-149.
Mackey JR, Ramos-Vazquez M, Lipatov O, et al. (2015). Primary Results of ROSE/TRIO-12, a
Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab
to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical
Oncology 33,2:141-148.
Palmieri C, Cleator S, Kilburn LS, et al. (2014). NEOCENT: a randomised feasibility and
translational study comparing neoadjuvant endocrine therapy with chemotherapy in ERrich postmenopausal primary breast cancer. Breast Cancer Research & Treatment
148,3:581-590.
Piccart M, Hortobagyi GN, Campone M, et al. (2014). Everolimus plus exemestane for
hormone-receptor-positive, human epidermal growth factor receptor-2-negative
advanced breast cancer: overall survival results from BOLERO-2+. Annals of Oncology
25,12:2357-2362.
Robertson JF, Lindemann J, Garnett S, et al. (2014). A good drug made better: the
fulvestrant dose-response story. Clinical Breast Cancer 14,6:381-389.
Sikov WM, Berry DA, Perou CM, et al. (2015). Impact of the Addition of Carboplatin and/or
Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense
Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II
to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology
33,1:13-21.
Tan AR, Johannes H, Rastogi P, et al. (2015). Weekly paclitaxel and concurrent pazopanib
following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative
locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. Breast Cancer
Research & Treatment 149,1:163-169.
Tolaney SM, Barry WT, Dang CT, et al. (2015). Adjuvant paclitaxel and trastuzumab for
node-negative, HER2-positive breast cancer. New England Journal of Medicine 372,2:134141.
Tredan O, Campone M, Jassem J, et al. (2015). Ixabepilone alone or with cetuximab as firstline treatment for advanced/metastatic triple-negative breast cancer. Clinical Breast
Cancer 15,1:8-15.
3
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
PATHOLOGY, STAGING, POLYMORPHISMS, BIOMARKERS
Baselga J, Cortes J, Im SA, et al. (2014). Biomarker analyses in CLEOPATRA: a phase III,
placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2positive, first-line metastatic breast cancer. Journal of Clinical Oncology 32,33:3753-3761.
Berruti A, Amoroso V, Gallo F, et al. (2014). Pathologic complete response as a potential
surrogate for the clinical outcome in patients with breast cancer after neoadjuvant
therapy: a meta-regression of 29 randomized prospective studies. Journal of Clinical
Oncology 32,34:3883-3891.
Huxley N, Jones-Hughes T, Coelho H, et al. (2015). A systematic review and economic
evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA)
system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
Health technology assessment (Winchester, England) 19,2:1-216.
Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, et al. (2014). The prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer
Research & Treatment 148,3:467-476.
Lindner JL, Loibl S, Denkert C, et al. (2015). Expression of secreted protein acidic and rich
in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy+.
Annals of Oncology 26,1:95-100.
Ng T, Chan M, Khor CC, et al. (2014). The genetic variants underlying breast cancer
treatment-induced chronic and late toxicities: a systematic review. Cancer treatment
reviews 40,10:1199-1214.
Rakha EA, Pinder SE, Bartlett JM, et al. (2015). Updated UK Recommendations for HER2
assessment in breast cancer. Journal of clinical pathology 68,2:93-99.
Treilleux I, Arnedos M, Cropet C, et al. (2015). Translational studies within the TAMRAD
randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor
for everolimus efficacy in advanced breast cancer. Annals of Oncology 26,1:120-125.
PROGNOSIS, SURVIVAL, RISK FACTORS
Jansen LA, Backstein RM and Brown MH. (2014). Breast size and breast cancer: a
systematic review. Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS 67,12:16151623.
Loibl, S. (2015). Neoadjuvant treatment of breast cancer: maximizing pathologic complete
response rates to improve prognosis. Current opinion in obstetrics & gynecology 27,1:85-91.
Mayer EL, Gropper AB, Harris L, et al. (2015). Long-Term Follow-Up After Preoperative
Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer. Clinical Breast
Cancer 15,1:24-30.
Noels EC, Lapid O, Lindeman JH, et al. (2015). Breast implants and the risk of breast
cancer: a meta-analysis of cohort studies. Aesthetic Surgery Journal 35,1:55-62.
Rakha EA, Tan PH, Varga Z, et al. (2015). Prognostic factors in metaplastic carcinoma of
the breast: a multi-institutional study. British journal of cancer 112,2:283-289.
4
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Winter AC, Rice MS, Fortner RT, et al. (2015). Migraine and breast cancer risk: a
prospective cohort study and meta-analysis. Journal of the National Cancer Institute
107,1:381.
Wuttke M and Phillips KA. (2015). Clinical management of women at high risk of breast
cancer. Current opinion in obstetrics & gynecology 27,1:6-13.
RADIOTHERAPY AND IMAGING
Connolly RM, Leal JP, Goetz MP, et al. (2015). TBCRC 008: Early Change in 18F-FDG
Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human
Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. Journal of
Nuclear Medicine 56,1:31-37.
Coudert B, Pierga JY, Mouret-Reynier MA, et al. (2014). Use of [(18)F]-FDG PET to predict
response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive
breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in
[(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised
phase 2 trial. Lancet Oncology 15,13:1493-1502.
Gilbert FJ, Tucker L, Gillan MG, et al. (2015). The TOMMY trial: a comparison of
TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme a multicentre retrospective reading study comparing the diagnostic performance of
digital breast tomosynthesis and digital mammography with digital mammography alone.
Health technology assessment (Winchester, England) 19,4:1-136.
Hu Q, Wang XY, Zhu SY, et al. (2015). Meta-analysis of contrast-enhanced ultrasound for
the differentiation of benign and malignant breast lesions. Acta radiologica 56,1:25-33.
Jagsi R, Falchook AD, Hendrix LH, et al. (2014). Adoption of hypofractionated radiation
therapy for breast cancer after publication of randomized trials. International journal of
radiation oncology, biology, physics 90,5:1001-1009.
Jagsi R, Griffith KA, Heimburger D, et al. (2014). Choosing wisely? Patterns and correlates
of the use of hypofractionated whole-breast radiation therapy in the state of michigan.
International journal of radiation oncology, biology, physics 90,5:1010-1016.
Moy L, Newell MS, Mahoney MC, et al. (2014). ACR Appropriateness Criteria stage I breast
cancer: initial workup and surveillance for local recurrence and distant metastases in
asymptomatic women. Journal of the American College of Radiology 11,12 Pt A:1160-1168.
Palta M, Palta P, Bhavsar NA, et al. (2015). The use of adjuvant radiotherapy in elderly
patients with early-stage breast cancer: Changes in practice patterns after publication of
Cancer and Leukemia Group B 9343. Cancer 121,2:188-193.
Sekiguchi K, Ogawa Y, Sanuki N, et al. (2015). The Japanese Breast Cancer Society clinical
practice guideline for radiotherapy of breast cancer. Breast Cancer 22,1:49-58.
Warren LE, Punglia RS, Wong JS, et al. (2014). Management of the regional lymph nodes
following breast-conservation therapy for early-stage breast cancer: an evolving
paradigm. International journal of radiation oncology, biology, physics 90,4:772-777.
SUPPORTIVE CARE AND SYMPTOM MANAGEMENT
5
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Asbury N, Lalayiannis L and Walshe A. (2014). How do I tell the children? Women's
experiences of sharing information about breast cancer diagnosis and treatment.
European Journal of Oncology Nursing 18,6:564-570.
Assi H, Murray J, Boyle L, et al. (2014). Incidence of febrile neutropenia in early stage
breast cancer patients receiving adjuvant FEC-D treatment. Supportive Care in Cancer
22,12:3227-3234.
Belmonte R, Monleon S, Bofill N, et al. (2015). Long thoracic nerve injury in breast cancer
patients treated with axillary lymph node dissection. Supportive Care in Cancer 23,1:169175.
Fallowfield L and Jenkins V. (2015). Psychosocial/survivorship issues in breast cancer: are
we doing better?. Journal of the National Cancer Institute 107,1:335.
Jensen CG, Elsass P, Neustrup L, et al. (2014). What to listen for in the consultation. Breast
cancer patients' own focus on talking about acceptance-based psychological coping
predicts decreased psychological distress and depression. Patient Education & Counseling
97,2:165-172.
Lee MK, Yun YH, Park HA, et al. (2014). A Web-based self-management exercise and diet
intervention for breast cancer survivors: pilot randomized controlled trial. International
journal of nursing studies 51,12:1557-1567.
Lepore SJ, Buzaglo JS, Lieberman MA, et al. (2014). Comparing standard versus prosocial
internet support groups for patients with breast cancer: a randomized controlled trial of
the helper therapy principle. Journal of Clinical Oncology 32,36:4081-4086.
Lewis L, Carson S, Bydder S, et al. (2014). Evaluating the effects of aluminum-containing
and non-aluminum containing deodorants on axillary skin toxicity during radiation
therapy for breast cancer: a 3-armed randomized controlled trial. International journal of
radiation oncology, biology, physics 90,4:765-771.
Obadina ET, Dubenske LL, McDowell HE, et al. (2014). Online support: Impact on anxiety in
women who experience an abnormal screening mammogram. Breast 23,6:743-748.
Potter JL, Collins CE, Brown LJ, et al. (2014). Diet quality of Australian breast cancer
survivors: a cross-sectional analysis from the Australian Longitudinal Study on Women's
Health. Journal of Human Nutrition & Dietetics 27,6:569-576.
Rogers LQ, Courneya KS, Anton PM, et al. (2015). Effects of the BEAT Cancer physical
activity behavior change intervention on physical activity, aerobic fitness, and quality of
life in breast cancer survivors: a multicenter randomized controlled trial. Breast Cancer
Research & Treatment 149,1:109-119.
Schover LR, Baum GP, Fuson LA, et al. (2014). Sexual problems during the first 2 years of
adjuvant treatment with aromatase inhibitors. Journal of Sexual Medicine 11,12:3102-3111.
Stearns V, Chapman JA, Ma CX, et al. (2015). Treatment-Associated Musculoskeletal and
Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant
Breast Cancer Aromatase Inhibitor Trial. Journal of Clinical Oncology 33,3:265-271.
Taghian NR, Miller CL, Jammallo LS, et al. (2014). Lymphedema following breast cancer
treatment and impact on quality of life: a review. Critical Reviews in Oncology-Hematology
92,3:227-234.
Trinh L, Mutrie N, Campbell AM, et al. (2014). Effects of supervised exercise on motivational
outcomes in breast cancer survivors at 5-year follow-up. European Journal of Oncology
Nursing 18,6:557-563.
6
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Vargas S, Antoni MH, Carver CS, et al. (2014). Sleep quality and fatigue after a stress
management intervention for women with early-stage breast cancer in southern Florida.
International Journal of Behavioral Medicine 21,6:971-981.
White VM, Young MA, Farrelly A, et al. (2014). Randomized Controlled Trial of a TelephoneBased Peer-Support Program for Women Carrying a BRCA1 or BRCA2 Mutation: Impact
on Psychological Distress. Journal of Clinical Oncology 32,36:4073-4080.
Yuste Sanchez MJ, Lacomba MT, Sanchez BS, et al. (2015). Health related quality of life
improvement in breast cancer patients: Secondary outcome from a simple blinded,
randomised clinical trial. Breast 24,1:75-81.
SURGERY
Carstensen L and Bigaard J. (2015). Management of central breast tumours with immediate
reconstruction of the nipple-areola complex; a suggested guide. Breast 24,1:38-45.
Julian TB, Venditti CA and Duggal S. (2015). Landmark Clinical Trials Influencing Surgical
Management of Non-invasive and Invasive Breast Cancer. Breast Journal 21,1:60-66.
Komoike Y, Inokuchi M, Itoh T, et al. (2015). Japan Breast Cancer Society clinical practice
guideline for surgical treatment of breast cancer. Breast Cancer 22,1:37-48.
Parvez E, Cornacchi SD, Hodgson N, et al. (2014). A cosmesis outcome substudy in a
prospective, randomized trial comparing radioguided seed localization with standard
wire localization for nonpalpable, invasive, and in situ breast carcinomas. American
Journal of Surgery 208,5:711-718.
Quinn EM, Kealy R, O'Meara S, et al. (2015). Is there a role for locoregional surgery in stage
IV breast cancer?. Breast 24,1:32-37.
Sierink JC, de Castro SM, Russell NS, et al. (2014). Treatment strategies in elderly breast
cancer patients: Is there a need for surgery?. Breast 23,6:793-798.
Soran A, Kamali Polat A, Johnson R, et al. (2014). Increasing trend of contralateral
prophylactic mastectomy: what are the factors behind this phenomenon?. Surgeon
Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland 12,6:316-322.
Verheuvel NC, van den Hoven I, Ooms HW, et al. (2015). The Role of Ultrasound-Guided
Lymph Node Biopsy in Axillary Staging of Invasive Breast Cancer in the Post-ACOSOG
Z0011 Trial Era. Annals of Surgical Oncology 22,2:409-415.
Winters ZE, Emson M, Griffin C, et al. (2015). Learning from the QUEST multicentre
feasibility randomization trials in breast reconstruction after mastectomy. British Journal
of Surgery 102,1:45-56.
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
7
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Sources used for this bulletin: OVID MEDLINE, SIGN, NICE, Healthcare Improvement Scotland
8
Breast Cancer, January 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network